Antibody-based cancer immunotherapies and how they work
Official title: Molecular mechanisms of antibody-mediated immunotherapies
Funded at Rockefeller University · NIH-11401814 · Data updated 2026-11-12
A researcher at Rockefeller University is studying how cancer-fighting antibodies trigger immune responses and how to make them work even better in people with advanced cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2016 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,017,000 |
| NIH project number | 5R35CA196620-12 |
| Project ID | NIH-11401814 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced cancer who are eligible for antibody-based immunotherapies and participate in related clinical trials.
✕Less likely to help
Some patients may not respond to these specific antibody strategies or may experience side effects.
What this research studies
This project looks at how antibodies that target tumors interact with the immune system to fight cancer, and how to optimize these interactions to improve patient outcomes. It aims to understand how Fc-FcγR pathways contribute to tumor elimination and to test strategies that boost memory immune responses to prevent recurrences. The work includes exploring how to vaccinate tumors with monoclonal antibodies, how certain antibody therapies can enhance immune activation, and how the tumor environment can be tweaked to support stronger anti-tumor immunity. Some therapies developed through this program are already in clinical trials with early signs of activity. The goal is to translate mechanistic insights into therapies that provide durable, long-term control of cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibody therapies that produce lasting immune memory and longer survival for patients with advanced cancers.
How similar studies have gone: Earlier work shows that Fc-engineered antibodies can improve clinical activity and survival in cancer patients.
Where this research is happening
-
Rockefeller University
New York, United States Active
Researchers
- Principal investigator: Ravetch, Jeffrey Victor — Rockefeller University
- Study coordinator: Ravetch, Jeffrey Victor
Related research
Other NIH-funded projects on the same topics.
-
How cells organize into organized tissues to form organs
Researchers are studying how human-like cells in a lab can self-organize within a scaffold to form orderly tissue patterns, which could illuminate how organs such as skin and bones develop.
-
Modeling Ataxia Telangiectasia in a human stem cell model of Purkinje cells
Researchers are creating a patient-derived, human cell model of Purkinje cells to understand why this brain disease causes cerebellar degeneration in people with Ataxia Telangiectasia.
-
Centers studying how cancer spreads through the body
A multi-institutional project at Rockefeller University is exploring how nerves, blood vessels, lymphatics, immune cells, and metabolites influence the spread of cancer to help identify new ways to stop metastasis.
-
Understanding how mycobacterial transcription works to guide better TB drugs
Researchers will study how the RNA polymerase of Mycobacterium tuberculosis and related bacteria start, pause, and finish copying genetic information, with the goal of informing new antibiotic strategies against TB.
-
How chromosomes stay true when cells divide in cancer research
Researchers are studying how chromosomes are accurately copied and distributed during cell division to understand and potentially prevent cancer.
-
Marmoset model of Huntington's disease shows how symptoms relate to brain and behavior
A researcher at a top university is studying how Huntington's disease affects brain signals and behavior in marmosets to better understand the human condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.